{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:09:01Z","timestamp":1761581341679,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.clgc.2015.08.008","type":"journal-article","created":{"date-parts":[[2015,9,2]],"date-time":"2015-09-02T22:56:59Z","timestamp":1441234619000},"page":"e9-e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"14","author":[{"given":"Takahiro","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutushi","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromasa","family":"Tsukino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shusuke","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinari","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Segawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Sugino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Kamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Kamba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2015.08.008_bib1","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2015.08.008_bib2","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2015.08.008_bib3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jjco\/hyn029","article-title":"Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan","volume":"38","author":"Naito","year":"2008","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2015.08.008_bib4","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s10147-012-0443-3","article-title":"Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients","volume":"18","author":"Kita","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.clgc.2015.08.008_bib5","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/j.1464-410X.2011.10201.x","article-title":"The use of estramustine phosphate in the\u00a0modern management of advanced prostate cancer","volume":"108","author":"Ravery","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2015.08.008_bib6","first-page":"2005","article-title":"Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate","volume":"12","author":"Pienta","year":"1994","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.clgc.2015.08.008_bib7","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S1470-2045(07)70284-X","article-title":"Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data","volume":"8","author":"Fizazi","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2015.08.008_bib8","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2015.08.008_bib9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s12032-013-0717-2","article-title":"Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature","volume":"30","author":"Matsumoto","year":"2013","journal-title":"Med Oncol"},{"key":"10.1016\/j.clgc.2015.08.008_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000085926","article-title":"Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy","volume":"75","author":"Hirano","year":"2005","journal-title":"Urol Int"},{"key":"10.1016\/j.clgc.2015.08.008_bib11","first-page":"71","article-title":"Advantages of second line estramustine for overall survival of hormone-refractory prostate cancer (HRPC) patients","volume":"10","author":"Naiki","year":"2009","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.clgc.2015.08.008_bib12","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1007\/s12032-012-0178-z","article-title":"Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer","volume":"29","author":"Minato","year":"2012","journal-title":"Med Oncol"},{"key":"10.1016\/j.clgc.2015.08.008_bib13","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1158\/0008-5472.CAN-12-4414","article-title":"A\u00a0road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer","volume":"73","author":"Mitsiades","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2015.08.008_bib14","first-page":"1057","article-title":"Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer","volume":"35","author":"Afshar","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clgc.2015.08.008_bib15","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/jnci\/djt280","article-title":"Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy","volume":"105","author":"Halabi","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2015.08.008_bib16","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.clgc.2015.03.004","article-title":"Low-dose estramustine phosphate and concomitant low-dose acetylsalicylic acid in heavily pretreated patients with advanced castration-resistant prostate cancer","volume":"13","author":"Petrioli","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2015.08.008_bib17","first-page":"42","article-title":"Androgen deprivation therapy and the re-emergence of parenteral estrogen in prostate cancer","volume":"10","author":"Phillips","year":"2014","journal-title":"Oncol Hematol Rev"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767315002220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767315002220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:27:17Z","timestamp":1761564437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767315002220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1558767315002220"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2015.08.008","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2015.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}